Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal


Klassificering: C

Preparat: Betmiga

ATC kod: G04BD12

Substanser: mirabegron


Exponeringen är större hos kvinnor men dosjustering enbart baserat på kön bedöms inte som nödvändig.

Majoriteten av försökspersonerna i de kliniska studierna var kvinnor och analyser av skillnader mellan män och kvinnor gällande effekt och biverkningar baseras på sammanslagna resultat från dessa studier. Könskillnader i behandlingseffekt är sannolikt till stor del relaterade till könsskillnader i symtombild.

En liten studie har visat att höga doser mirabegron gav QT-förlängning hos kvinnor men inte hos män.

Additional information

The selective beta-3 adrenoreceptor agonist mirabegron induce relaxation of the bladder detrusor muscle and is used to treat urgency incontinence and symptoms of overactive bladder. Due to differences in possible etiology of these symptoms in men and women mirabegron’s place in therapy is slightly different. In women, mirabegron treatment is used as an alternative to anticholinergics when non-pharmacological treatments such as bladder training are insufficient. In men, benign prostate hyperplasia is a possible cause of urgency symptoms. Other drugs, primarily alpha-1 blockers, are therefore common as first-line treatments. However, mirabegron can be used in addition to drugs for benign prostate hyperplasia or as monotherapy as an alternative to anticholinergic drugs [1].The baseline symptoms described in studies differ between men and women regarding prevalence of incontinence episodes and frequency of urgency episodes [2, 3]. Treatment effects on these parameters are common outcomes in clinical studies and differences in treatment effect between men and women need to be interpreted in relation to differences at baseline.The placebo effect seen in clinical studies of overactive bladder treatment is relatively high. According to a meta-analysis, 41% of the patients in placebo groups report cure or symptom improvement [4]. Two other meta-analysis report that changes from baseline with placebo treatment are significant for mean micturitions, mean incontinence episodes and mean voided volume [5, 6]. Most studies include more women than men, and the low number of men included can affect the ability to make statistically significant analysis.

Pharmacokinetics and dosing

According to the manufacturer’s documentation to FDA, clinical studies showed that Cmax and AUC are 40-50% higher in women. After adjusting for body weight the difference was 20-30% [7]. Data from two pharmacokinetic studies (65 men, 38 women) showed that after a single dose mirabegron AUC was 27% and 64% higher in women, for IV and PO administration respectively. These differences were largely due to differences in body weight and in the case of oral treatment also absolute bioavailability. Similarly, clearance was lower in women than in men mostly due to differences in weight and bioavailability [8]. Another study on healthy individuals (32 young men, 32 young women, 16 elderly men, 16 elderly women) given multiple doses, 50 to 300 mg, of an oral controlled absorption mirabegron tablet. Both Cmax and AUC was about 40% higher in women. After adjustment for body weight the difference was 20% [10]. A study on healthy East Asian subjects showed similar sex differences regarding pharmacokinetic parameters [11].

The exposure of mirabegron is decreased by food intake and this effect has been shown to be similar in men and women [12].

No sex differentiation in dosing has been recommended by the manufacturer [7]. The dosing recommendation differs between EU and the US. The recommended starting dose in both men and women with normal kidney and liver function and without concurrent use of CYP3A inhibitors is 50 mg in EU. In the US the recommended starting dose is 25 mg, with possible increase to 50 mg after 8 weeks based on efficacy. In general women have higher CYP3A4 activity [13].


Based on data from three phase 3 studies the mean reduction from baseline regarding incontinence episodes was larger in women, men were less likely than women to have incontinence episodes at baseline though. Mirabegron has been reported to reduce incontinence episodes and micturations in both men and women [7].

Adverse effects

In a cross over safety study including healthy subjects (22 men and 22 women) supratherapeutic doses of 200 mg mirabegron caused prolonged QTc in women but not in men. At therapeutic doses of 50 mg and supratherapeutic doses of 100 mg no QTc prolongation was found in either sex [14].

The major clinical studies of mirabegron treatment include mostly women (between 69-89%). In a pooled analysis of data from four phase 3 studies, three 12 week and one 12 month study, sex differences regarding safety and tolerability was evaluated. The overall frequency of treatment emergent adverse effects in the 12 week studies was higher in women, however the difference compared to placebo was similar between sexes. Most adverse effects were also more common in women, with the notable exception of hypertension. No significant difference between men and women regarding overall adverse effects was seen in the 12 month study [15].

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Other information

Patient satisfaction with anticholinergic treatment was evaluated in a survey study in Japanese patients with overactive bladder syndrome (in total 514 men, 455 women). In the entire study one third of all patients were satisfied and one third dissatisfied with their treatment, men were overall less satisfied than women. Dissatisfaction was commonly influenced by poor efficacy or adverse effects, mainly constipation [9].

Försäljning på recept

Fler kvinnor än män hämtade ut tabletter innehållande mirabegron (ATC-kod G04BD12) på recept i Sverige år 2015, totalt 17 565 kvinnor och 10 902 män. Det motsvarar 3,6 respektive 2,2 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 70 år och äldre hos båda könen. I genomsnitt var tabletter innehållande mirabegron 2,2 gånger vanligare hos kvinnor [16].

Uppdaterat: 2020-08-28

Litteratursökningsdatum: 2015-03-12


  1. Suarez O, Osborn D, Kaufman M, Reynolds WS, Dmochowski R. Mirabegron for male lower urinary tract symptoms. Curr Urol Rep. 2013;14:580-4. PubMed
  2. Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009;104:352-60. PubMed
  3. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306-14; discussion 1314-5. PubMed
  4. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006;18:CD003781. PubMed
  5. Lee S, Malhotra B, Creanga D, Carlsson M, Glue P. A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Med Res Methodol. 2009;9:55. PubMed
  6. Mangera A, Chapple CR, Kopp ZS, Plested M. The placebo effect in overactive bladder syndrome. Nat Rev Urol. 2011;8:495-503. PubMed
  7. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - MYRBETRIQ (mirabegron).
  8. Eltink C, Lee J, Schaddelee M, Zhang W, Kerbusch V, Meijer J et al. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder. Int J Clin Pharmacol Ther. 2012;50:838-50. PubMed
  9. Akino H, Namiki M, Suzuki K, Fuse H, Kitagawa Y, Miyazawa K et al. Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study. Int J Urol. 2014;21:389-94. PubMed
  10. Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G et al. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther. 2012;34:2144-60. PubMed
  11. Iitsuka H, van Gelderen M, Katashima M, Takusagawa S, Sawamoto T. Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects. Clin Ther. 2015;37:1031-44. PubMed
  12. Lee J, Zhang W, Moy S, Kowalski D, Kerbusch V, van Gelderen M et al. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults. Clin Ther. 2013;35:333-41. PubMed
  13. BETMIGA (mirabegron). Summary of Product Characteristics. European Medicines Agency (EMA); 2012.
  14. Malik M, van Gelderen EM, Lee JH, Kowalski DL, Yen M, Goldwater R et al. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther. 2012;92:696-706. PubMed
  15. Nitti VW, Chapple CR, Walters C, Blauwet MB, Herschorn S, Milsom I et al. Safety and tolerability of the β3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial. Int J Clin Pract. 2014;68:972-85. PubMed
  16. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.] länk

Författare: Ludvig Petersson, Desirée Loikas

Faktagranskat av: Mia von Euler

Godkänt av: Karin Schenck-Gustafsson